| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.075 | 0.02 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.12 | 0.03 |